Ipstyl Autogel

Lanreotide, the active ingredient in Ipstyl Autogel, is a somatostatin analog presented as a gel (Autogel) for subcutaneous injection use. It is employed to control excess growth hormone production in adults with acromegaly and to manage hormone‑secreting neuroendocrine tumors.

GNH USA supplies Ipstyl Autogel as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide with a focus on quality assurance and regulatory compliance.

Lanreotide is used in the management of hormone‑dependent disorders affecting the growth hormone axis and neuroendocrine secretion.

Acromegaly: reduces serum growth hormone and IGF‑1 levels, helping control disease activity. Neuroendocrine tumors: inhibits hormone secretion and may slow tumor progression. Carcinoid syndrome (functional NETs): alleviates flushing and diarrhea by suppressing vasoactive peptide release.

Common Side Effects: - Injection site pain or erythema - Abdominal discomfort or cramps - Diarrhoea or constipation - Nausea or vomiting - Headache - Mild hyperglycaemia

Serious or Rare Side Effects: - Gallstone formation or biliary colic - Acute pancreatitis - Severe hypersensitivity reactions (anaphylaxis, angioedema) - Significant hyperglycaemia or new‑onset diabetes - Cardiac arrhythmias - Severe hepatic dysfunction

Lanreotide requires careful monitoring in several clinical situations.

Pregnancy: consult a healthcare provider; limited safety data are available. Breastfeeding: avoid unless the benefit outweighs potential risk to the infant. Renal impairment: monitor renal function; dose adjustment may be needed. Diabetes or impaired glucose tolerance: observe blood‑glucose levels as the drug can affect glycaemic control. Gallbladder disease: use with caution due to increased risk of gallstone formation. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Lanreotide may interact with other medicines that influence hormone levels or cardiac conduction.

Major Interactions (Avoid): - Concurrent use of other somatostatin analogs: additive hormone suppression and heightened gallstone risk. - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase lanreotide exposure. - Medications that prolong the QT interval: combined effect may raise the risk of cardiac arrhythmias.

Moderate Interactions (Monitor Closely): - Insulin or oral hypoglycaemic agents: lanreotide can alter glucose control, requiring dose adjustments. - Anticholinergic drugs: may exacerbate gastrointestinal side effects such as constipation.